4 recruiting, 2 not yet recruiting, 1 enrolling by invitation. 4 Phase 2, 1 Early Phase 1, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 3, Not yet recruiting 1 |
| Early Phase 1 | 1 | Enrolling by invitation 1 |
| Phase 3 | 1 | Recruiting 1 |
| Phase 4 | 1 | Not yet recruiting 1 |
Follow Immunoglobulin A Nephropathy (IgAN): new trials by email Literature Review of Immunoglobulin A Nephropathy (IgAN) trials Research Report on Immunoglobulin A Nephropathy (IgAN)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN ARGX-121, Placebo - Immunoglobulin A Nephropathy (IgAN) | Phase 2 | Recruiting | argenx | 120 | 2026-11-05 | 2026-10-27 |
| Mechanistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN) atrasentan - IgA Nephropathy (IgAN), Immunoglobulin A Nephropathy (IgAN) | Phase 4 | Not yet recruiting | University of Illinois at Chicago | 20 | 2026-09-29 | 2026-09-21 |
| Chinese Adults With Kidney Disease ADX-038, Telitacicept - Immunoglobulin A Nephropathy (IgAN), Complement 3 Glomerulopathy (C3G) | Phase 2 | Recruiting | ADARx Pharmaceuticals, Inc. | 30 | 2026-05-21 | 2026-09-03 |
| A Study to Assess the Effects of Zigakibart on IgA Nephropathy. zigakibart - Immunoglobulin A Nephropathy (IgAN) | Phase 2 | Recruiting | Novartis Pharmaceuticals | 32 | 2026-03-26 | 2026-10-21 |
| Efficacy and Safety Study of HS-10542 for IgA Nephropathy HS-10542 High Dose, HS-10542 Low Dose, Placebo - IgAN, Immunoglobulin A Nephropathy (IgAN) | Phase 2 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 90 | 2026-03-17 | 2026-03-16 |
| A Study of Cizutamig in Patients With Immunoglobulin A Nephropathy Biological: cizutamig - Immunoglobulin A Nephropathy (IgAN) | Early Phase 1 | Enrolling by invitation | Peking University First Hospital | 15 | 2025-07-16 | 2025-08-22 |
| A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) Felzartamab, Placebo - Immunoglobulin A Nephropathy (IgAN) | Phase 3 | Recruiting | Biogen | 454 | 2025-05-08 | 2026-10-14 |
Glomerulonephritis, IGA (7) · Fibrosis (1) · Glomerulonephritis, Membranoproliferative (1) · Proteinuria (1)
Autoimmune Diseases (7) · Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Glomerulonephritis (7) · Immune System Diseases (7) · Kidney Diseases (7) · Male Urogenital Diseases (7) · Nephritis (7) · Urogenital Diseases (7) · Urologic Diseases (7) · Pathological Conditions, Signs and Symptoms (2) · Pathologic Processes (1) · Signs and Symptoms (1) · Urination Disorders (1) · Urological Manifestations (1)
Atrasentan (1) · felzartamab (1) · telitacicept (1)
ADARx Pharmaceuticals, Inc. (1) · Biogen (1) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (1) · Novartis Pharmaceuticals (1) · Peking University First Hospital (1) · University of Illinois at Chicago (1) · argenx (1)
China (5) · United States (4) · Japan (3) · Brazil (2) · Czechia (2) · Germany (2) · Italy (2) · Poland (2) · South Korea (2) · Spain (2) · Taiwan (2) · Argentina (1) · Australia (1) · Belgium (1) · Bulgaria (1)
Anand Srivastava, MD, MPH (1) · Arezoo Mirad (1)